Vinblastine (Velban)
Jump to navigation
Jump to search
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Vinblastine (Velban) patient drug information (Chemocare)[3]
- Vinblastine (Velban) patient drug information (UpToDate)[4]
Diseases for which it is used
- Bladder cancer
- Breast cancer
- Diffuse large B-cell lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Melanoma
- Non-small cell lung cancer
- Testicular cancer
Also known as
- Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
- Brand names:
Synonyms | ||||
---|---|---|---|---|
Alkaban-AQ | Blastovin | Cellblastin | Cytoblastine | Erbablas |
Exal | Faulblastina | Lemblastine | Periblastine | Rabinefil |
Velban | Velbastine | Velbe | Vinblasin | Vinblastin |
Vinblastina |
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Bladder cancer medications
- Breast cancer medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Kaposi sarcoma medications
- Langerhans cell histiocytosis medications
- Melanoma medications
- Non-small cell lung cancer medications
- Testicular cancer medications
- FDA approved in 1965
- WHO Essential Cancer Medicine